OKUR Share Price Performance
Recent OKUR News & Updates
No updates
OnKure Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -4.37
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
OnKure Therapeutics, Inc. Competitors
About OKUR
- Founded
- n/a
- Employees
- 46
- CEO
- WebsiteView website
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
U.S. Market Performance
- 7 Days: -0.6%
- 3 Months: 11.8%
- 1 Year: 16.8%
- Year to Date: 7.5%
The market has been flat in the last week, however the Materials sector is down 4.1%. Meanwhile, the market is actually up 16% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading